


ABBREVIATIONS AND ACRONYMS



ABC	abacavir	MDR-TB	Multi-drug-resistant tuberculosis
ALD	abacavir/lamivudine/dolutegravir	MoH	Ministry of Health
AMR	Antimicrobial Resistance	MPP	Medicines Patent Pool
ANDA	Abbreviated New Drug Application	MSF	Médecins Sans Frontières
API	Active pharmaceutical ingredient	NARCs	Non-AIDS-related comorbidities
ARV	Antiretroviral	NCD	Non-communicable disease
ASCP	American Society of Clinical Pathology	NGO	Non-governmental organisation
ATOM	Access to Oncology Medicines	NMPA	China National Medical Products Administration
ATV	atazanavir	NSCLC	Non Small Cell Lung Cancer
BCS	Biopharmaceutical classification system	OEB	Occupational Exposure Bands
BE	Bioequivalence	OEL	Occupational Exposure Limits
CAB-LA	Cabotagravir long-acting	PAN-TB	Project to Accelerate New Treatments for Tuberculosis
CAP	Community Advisory Panel	PEPFAR	President's Emergency Plan for AIDS Relief
CHAI	Clinton Health Access Initiative	PFSCM	Partnership for Supply Chain Management
CKD	Chronic Kidney Diseases	PHEIC	Public health emergency of international concern
CLHIV	Children living with HIV	PK	Pharmacokinetics
CLL	Chronic Lymphocytic Leukemia	PLHCV	People living with HCV
CVD	Cardiovascular Diseases	PLHIV	People living with HIV
DAC	Daclatasvir	PPH	Post-partum haemorrhage
DNDi	Drugs for Neglected Diseases Initiative	PrEP	Pre-Exposure Prophylaxis
DTG	Dolutegravir	PROs	Public research organisations
EAG	Expert Advisory Group	PSA	Prostate-Specific Antigen
EASL	European Association for the Study of the Liver	r	ritonavir
EECA	Eastern Europe and Central Asia	RMNCH	Reproductive, maternal, newborn and child health
EGFR	Epidermal Growth Factor Receptor	RR-TB	Rifampicin-resistant tuberculosis
EMA	European Medicines Agency	RSV	Respiratory Syncytial Virus
EML	Essential Medicines List	SAP	Scientific Advisory Panel
EoI	Expression of Interest	SCD	Sickle Cell Disease
ESMO	European Society for Medical Oncology	SDC	Swiss Agency for Development Cooperation
EU-M4All	The European Medicines Agency (EMA), in cooperation with the World Health Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, that are intended for markets outside of the European Union (EU). The procedure is called EU-Medicines for all or 'EU-M4all'.	SOC	Standard of care
FDC	Fixed dose combination	SOF	sofosbuvir
FTC	Emtricitabine	SRAs	Stringent Regulatory Authorities
G/P	glecaprevir/pibrentasvir	SSA	Sub-Saharan Africa
G20	Group of twenty	Swissmedic	Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products
GAP-f	Global Accelerator for Paediatric Formulations	MAGHP	
GLP-1	Glucagon-like peptide-1	T1DM	Type 1 Diabetes
HbS	Sickle hemoglobin	T2DM	Type 2 Diabetes
HCV	Hepatitis C virus	TAF	Alafenamide
HDV	Hepatitis Delta Virus	TB	Tuberculosis
HER2	human epidermal growth factor receptor 2	The Global Fund	The Global Fund to Fight AIDS, Tuberculosis and Malaria
HICs	High income countries	TLD	tenofovir/lamivudine/dolutegravir
HIV	Human immunodeficiency virus	UCLA	University of California Los Angeles
HPV	Human papillomavirus	UHC	Universal Health Coverage
HR	Hormone Receptor	UK	United Kingdom
IAS	International Aids Society	UNAIDS	Joint United Nations Programme on HIV/AIDS
IDF	International Diabetes Federation	USD	United States Dollar
IP	Intellectual property	USFDA	The United States Food and Drug Administration
ITPC	International Treatment Preparedness Coalition	USFDA Para III	Paragraph III Certification means a certification that a generic applicant seeks FDA approval of its ANDA as of the date a patent listed in the Orange Book for a relevant NDA expires.
KRAS	Kirsten rat sarcoma virus	WHO	World Health Organization
LEN	lenacapavir	WHO PQ	WHO Prequalification of Medicines Programme
LMICs	Low- and middle-income countries		
LPV	lopinavir		
MAGHP	Marketing Authorisation for Global Health Products		